ITOS

iTeos Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website iteostherapeutics.com
Employees(FY) 125
ISIN US46565G1040

Performance

-3.91%

+1.1%

-14.2%

-57.81%

-4.04%

YTD

-25.93%

Profile

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Advanced Technical Analysis

Technical Analysis of ITOS 2025-02-03

The stock indicators reflect a predominantly bearish sentiment, with a Moving Average Score of 3 indicating strong bearish momentum, while the Oscillators Score of 40 suggests a neutral stance. However, the overall Technical Score of 9 reinforces the bearish outlook, signaling potential challenges for upward price movement in the near term.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ITOS

Stock Rank

Recent News & Updates

2024-07-08 07:54
iTeos Therapeutics Doses First Patient in Phase 3 Trial of Belrestotug With Dostarlimab; Triggers $35 Million GSK Payment(MT Newswires)
2024-07-08 07:00
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK(GlobeNewswire)
2024-07-07 19:00
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK(Globenewswire)
2024-07-05 10:08
iTeos, Arcus Shares Drop After Genentech's Lung Cancer Study Misses Endpoints(MT Newswires)
2024-06-18 06:33
iTeos Therapeutics and GSK begin Phase III trial of combination therapy for NSCLC(Clinical Trials Arena)
2024-06-17 09:00
iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer(GlobeNewswire)
2024-06-16 21:00
iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer(Globenewswire)
2024-06-05 07:54
Should Shareholders Reconsider iTeos Therapeutics, Inc.'s (NASDAQ:ITOS) CEO Compensation Package?(Simply Wall St.)
2024-05-13 08:28
HC Wainwright Adjusts Price Target on iTeos Therapeutics to $46 From $44, Maintains Buy Rating(MT Newswires)
2024-05-10 12:21
Wedbush Adjusts iTeos Therapeutics' Price Target to $21 From $18, Maintains Outperform Rating(MT Newswires)
2024-05-10 09:40
iTeos Therapeutics Q1 Net Loss Widens; Initiates $120 Million Registered Direct Offering -- Shares Jump(MT Newswires)
2024-05-10 08:26
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates(GlobeNewswire)
2024-05-10 08:24
iTeos Therapeutics Announces $120 Million Registered Direct Offering(GlobeNewswire)
2024-05-10 08:09
iTeos shares jump on TIGIT update; Acelyrin swaps CEOs(BioPharma Dive)
2024-05-10 01:53
ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q1 2024(Investorplace)
2024-05-09 20:26
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates(Globenewswire)
2024-05-09 20:24
iTeos Therapeutics Announces $120 Million Registered Direct Offering(Globenewswire)
2024-04-07 16:30
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024(GlobeNewswire)
2024-04-07 04:30
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024(Globenewswire)
2024-03-06 07:01
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors(GlobeNewswire)
2024-03-06 07:00
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates(GlobeNewswire)
2024-03-06 01:51
ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q4 2023(Investorplace)
2024-03-05 18:01
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors(Globenewswire)
2024-03-05 18:00
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates(Globenewswire)
2024-03-05 16:30
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024(GlobeNewswire)
2024-03-05 03:30
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024(Globenewswire)
2024-03-01 07:00
iTeos to Participate in Upcoming Investor Conferences(GlobeNewswire)
2024-02-29 18:00
iTeos to Participate in Upcoming Investor Conferences(Globenewswire)
2024-02-26 06:11
Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength?(Zacks)
2024-02-25 17:11
Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength?(Zacks)

Page 2 of 6

previous next

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.